Biocon quarterly net jumps 52%
Source: IRIS | 21 Oct, 2016, 10.20AM
|
|
|
|
Rating: NAN / 5 stars. |
Comments | Post Comment |
|
Kiran Mazumdar-Shaw, chairperson and managing director said, ''Our performance in Q2 FY17, was led by strong growth across Small Molecules, Biologics and Research Services. Expansion of our biologics footprint in emerging markets and licensing agreements boosted the revenue further. Our ready-to-use Insulin Glargine pen launched in Japan has been well received which augurs well for this business. The acceptance of our proposed biosimilar Trastuzumab filing for review by EMA was a critical milestone this quarter. This is our second filing in EU. The tentative USFDA approval for Rosuvastatin calcium tablets heralds our entry into the US generics market.''
|
|
|
|
|
|
|
|
|
|
|
|